• Donor Login
  • Contact Us
  • JDRF
JDRF T1D Fund
  • About
  • Investment Strategy
  • Portfolio
  • Our People
  • Venture Philanthropy
  • News
  • Donor Login
  • Get in touch

News and Press

Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets

April 13, 2021 | CAMBRIDGE, MA

T1D Fund in the News

Venture Models Can Accelerate Cures but Aren’t for the Faint of Heart

April 09, 2021 | HBS Kraft Precision Medicine Accelerator

Interview with portfolio company IM Therapeutics on HLA targeted immune therapy treatments

March 30, 2021

Taking gene therapy to the masses with innovations in diabetes, Alzheimer’s and more

March 30, 2021

eGenesis Announces $125 Million Series C Financing

March 02, 2021 | CAMBRIDGE, MA

About the JDRF T1D Fund

Our aim is to create a new investment market aimed at delivering solutions to those living with or at risk of developing T1D. Launched in December 2016, the T1D Fund is a combination of venture capital and philanthropy focused solely on T1D. It’s the first scale, mission-driven venture philanthropy fund focused on equity investments in companies developing life-changing T1D products. The portfolio consists of therapeutics, devices, vaccines, and diagnostics. We already have made several investments and the list will only continue to grow.


  • About
  • Investment
    Strategy
  • Portfolio
  • Our People
  • Venture
    Philanthropy
  • News
Contact Us

For more information email us at t1dfund@jdrf.org

JDRF T1D Fund

© Copyright 2018. All Rights Reserved